These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38548221)
1. Exploring the role of ghrelin and des-acyl ghrelin in chemotherapy-induced nausea and vomiting. Yang L; Kung CJS; Lu Z; Liu JYH; Ngan MP; Sakai T; Sakata I; Chan SW; Tu L; Rudd JA Neuropharmacology; 2024 Jun; 251():109919. PubMed ID: 38548221 [TBL] [Abstract][Full Text] [Related]
2. Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats. Jaime-Lara RB; Borner T; Holland RA; Shaulson E; Brooks B; De Jonghe BC Biol Res Nurs; 2021 Oct; 23(4):584-595. PubMed ID: 33789505 [TBL] [Abstract][Full Text] [Related]
3. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Lu Z; Ngan MP; Liu JYH; Yang L; Tu L; Chan SW; Giuliano C; Lovati E; Pietra C; Rudd JA Physiol Behav; 2024 Oct; 284():114644. PubMed ID: 39043357 [TBL] [Abstract][Full Text] [Related]
4. Comparison of three preclinical models for nausea and vomiting assessment. Goineau S; Castagné V J Pharmacol Toxicol Methods; 2016; 82():45-53. PubMed ID: 27477617 [TBL] [Abstract][Full Text] [Related]
5. An open multicentre study of tropisetron for cisplatin-induced nausea and vomiting. Olver IN; Craft PS; Clingan PR; Kearsley JH; Planner RS; van Hazel GA; Bell DR; Adena MR; Hall BE; Pearson LL Med J Aust; 1996 Mar; 164(6):337-40. PubMed ID: 8606657 [TBL] [Abstract][Full Text] [Related]
6. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Rudd JA; Ngan MP; Wai MK; King AG; Witherington J; Andrews PL; Sanger GJ Neurosci Lett; 2006 Jan; 392(1-2):79-83. PubMed ID: 16182445 [TBL] [Abstract][Full Text] [Related]
7. Xiaobanxia decoction alleviates chemotherapy-induced nausea and vomiting by inhibiting GSDME-mediated pyroptosis. Liao X; Ye B; Hu W; Han J; Zhao Y; Dai Y; Wu X; Mo Z; Wei L; Nie K J Ethnopharmacol; 2024 Jan; 318(Pt B):116970. PubMed ID: 37516392 [TBL] [Abstract][Full Text] [Related]
8. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret. Warneck JB; Cheng FH; Barnes MJ; Mills JS; Montana JG; Naylor RJ; Ngan MP; Wai MK; Daiss JO; Tacke R; Rudd JA Toxicol Appl Pharmacol; 2008 Nov; 232(3):369-75. PubMed ID: 18675289 [TBL] [Abstract][Full Text] [Related]
10. Antiemetic effect of a potent and selective neurokinin-1 receptor antagonist, FK886, on cisplatin-induced acute and delayed emesis in ferrets. Furukawa TY; Nakayama H; Imazumi K; Yamakuni H; Takeshita K; Matsuo M; Manda T; Uchida W Biol Pharm Bull; 2014; 37(2):232-8. PubMed ID: 24492720 [TBL] [Abstract][Full Text] [Related]
11. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Hesketh PJ; Roman A; Hesketh AM; Perez EA; Edelman M; Gandara DR Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897 [TBL] [Abstract][Full Text] [Related]
12. Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. Nakayama H; Yamakuni H; Higaki M; Ishikawa H; Imazumi K; Matsuo M; Mutoh S J Pharmacol Sci; 2005 Aug; 98(4):396-403. PubMed ID: 16079468 [TBL] [Abstract][Full Text] [Related]
13. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Cocquyt V; Van Belle S; Reinhardt RR; Decramer ML; O'Brien M; Schellens JH; Borms M; Verbeke L; Van Aelst F; De Smet M; Carides AD; Eldridge K; Gertz BJ Eur J Cancer; 2001 May; 37(7):835-42. PubMed ID: 11313170 [TBL] [Abstract][Full Text] [Related]
14. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy. Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting. Voravud N; Sriuranpong V J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). De Jonghe BC; Horn CC Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R902-11. PubMed ID: 19225146 [TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists. Percie du Sert N; Rudd JA; Apfel CC; Andrews PL Cancer Chemother Pharmacol; 2011 Mar; 67(3):667-86. PubMed ID: 20509026 [TBL] [Abstract][Full Text] [Related]
18. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research. Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. Chang TC; Hsieh F; Lai CH; Tseng CJ; Cheng HH; Li CL; Michael BJ; Soong YK Cancer Chemother Pharmacol; 1996; 37(3):279-85. PubMed ID: 8529290 [TBL] [Abstract][Full Text] [Related]
20. Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron. Goineau S; Guillaume P; Barrais L; Castagné V Fundam Clin Pharmacol; 2014 Dec; 28(6):643-51. PubMed ID: 24750138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]